Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 3/2015

01.03.2015 | Maternal-Fetal Medicine

Survey of obstetrician-gynecologists in the United States about toxoplasmosis: 2012 update

verfasst von: Stephanie M. Davis, Britta L. Anderson, Jay Schulkin, Katherine Jones, Jodi Vanden Eng, Jeffrey L. Jones

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Toxoplasmosis, caused by the parasite Toxoplasma gondii, can have serious impacts on fetal development in the setting of acute maternal primary infection. The American College of Obstetricians and Gynecologists (ACOG) sought to determine current knowledge, practices, opinions, and educational preferences regarding T. gondii infection in pregnancy among ACOG members practicing prenatal care.

Methods

ACOG sent a survey to 1,056 members chosen by stratified random sampling from membership lists, including 370 participants and 686 non-participants in the Collaborative Ambulatory Research Network (CARN). Mailings were sent up to four times to nonresponders.

Results

Survey minimum response rates were 40.3 % (CARN) and 19.7 % (non-CARN); response rates adjusted for imputed non-eligibility were 59.7 % (CARN) and 22.6 % (non-CARN). Among providers, 80.2 % had diagnosed no acute maternal T. gondii infections in the past 5 years, 12.7 % correctly identified the screening role of the Toxoplasma avidity test, 42.6 % performed serologic T. gondii screening for at least some asymptomatic pregnant women, and 62.1 % of those who so did used appropriate approaches. Providers in the northeastern United States were 2.02 times more likely to routinely screen than those in the west (p = 0.025) and female providers were 1.48 times more likely than male providers (p = 0.047). The potential educational interventions considered useful by the most practitioners were updated ACOG guidelines on screening (81.4 %) and management (71.7 %) for acute T. gondii infection in pregnancy.

Conclusions

ACOG members would benefit from educational efforts targeted at risk factor counseling and screening approaches.
Fußnoten
1
“Acceptable” screening methods included checking both IgG and IgM; checking IgG alone repeatedly (allowing ascertainment of seroconversion); or checking IgM if then confirmed with IgM and IgG.
 
Literatur
1.
Zurück zum Zitat Jones JL, Dietz VJ, Power M, Lopez A, Wilson M, Navin TR, Gibbs R, Schulkin J (2001) Survey of obstetrician-gynecologists in the United States about toxoplasmosis. Infect Dis Obstet Gynecol 9:23–31PubMedCentralPubMedCrossRef Jones JL, Dietz VJ, Power M, Lopez A, Wilson M, Navin TR, Gibbs R, Schulkin J (2001) Survey of obstetrician-gynecologists in the United States about toxoplasmosis. Infect Dis Obstet Gynecol 9:23–31PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Jones JL, Krueger A, Schulkin J, Schantz PM (2009) Toxoplasmosis prevention and testing in pregnancy, survey of obstetrician-gynaecologists. Zoonoses Public Health 57:27–33PubMedCrossRef Jones JL, Krueger A, Schulkin J, Schantz PM (2009) Toxoplasmosis prevention and testing in pregnancy, survey of obstetrician-gynaecologists. Zoonoses Public Health 57:27–33PubMedCrossRef
3.
Zurück zum Zitat ACOG Practice Bulletin: perinatal viral and parasitic infections no. 20 (2000). Int J Gynecol Obstet 76: 95–107 ACOG Practice Bulletin: perinatal viral and parasitic infections no. 20 (2000). Int J Gynecol Obstet 76: 95–107
5.
Zurück zum Zitat Jones JL, Kruszon-Moran D, Sanders-Lewis K, Wilson M (2007) Toxoplasma gondii infection in the United States, 1999–2004, decline from the prior decade. Am J Trop Med Hyg 77:405–410PubMed Jones JL, Kruszon-Moran D, Sanders-Lewis K, Wilson M (2007) Toxoplasma gondii infection in the United States, 1999–2004, decline from the prior decade. Am J Trop Med Hyg 77:405–410PubMed
6.
Zurück zum Zitat Alford CA Jr, Stagno S, Reynolds DW (1974) Congenital toxoplasmosis: clinical, laboratory, and therapeutic considerations, with special reference to subclinical disease. Bull N Y Acad Med 50:160–181PubMedCentralPubMed Alford CA Jr, Stagno S, Reynolds DW (1974) Congenital toxoplasmosis: clinical, laboratory, and therapeutic considerations, with special reference to subclinical disease. Bull N Y Acad Med 50:160–181PubMedCentralPubMed
7.
Zurück zum Zitat Kimball AC, Kean BH, Fuchs S (1971) Congenital toxoplasmosis: a prospective study of 4,048 obstetric patients. Am J Obstet Gynecol 111:211–218PubMed Kimball AC, Kean BH, Fuchs S (1971) Congenital toxoplasmosis: a prospective study of 4,048 obstetric patients. Am J Obstet Gynecol 111:211–218PubMed
8.
Zurück zum Zitat Guerina NG, Hsu HW, Meissner HC, Maguire JH, Lynfield R, Stechenberg B, Abroms I, Pasternack, Hoff R, Eaton RB, Grady GF, New England Regional Toxoplasma Working Group (1994) Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. N Engl J Med 330:1858–1863PubMedCrossRef Guerina NG, Hsu HW, Meissner HC, Maguire JH, Lynfield R, Stechenberg B, Abroms I, Pasternack, Hoff R, Eaton RB, Grady GF, New England Regional Toxoplasma Working Group (1994) Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. N Engl J Med 330:1858–1863PubMedCrossRef
9.
Zurück zum Zitat Lopez A, Dietz V, Wilson M, Navin TR, Jones JL (2000) Preventing congenital toxoplasmosis. MMWR Recomm Rep 49:37–75 Lopez A, Dietz V, Wilson M, Navin TR, Jones JL (2000) Preventing congenital toxoplasmosis. MMWR Recomm Rep 49:37–75
11.
Zurück zum Zitat Cvetković D, Bobić B, Jankovska G, Klun I, Panovski N, Djurković-Djaković O (2010) Risk factors for Toxoplasma infection in pregnant women in FYR of Macedonia. Parasite 17(3):183–186PubMedCrossRef Cvetković D, Bobić B, Jankovska G, Klun I, Panovski N, Djurković-Djaković O (2010) Risk factors for Toxoplasma infection in pregnant women in FYR of Macedonia. Parasite 17(3):183–186PubMedCrossRef
13.
Zurück zum Zitat Dubey JP (1994) Toxoplasmosis. J Am Vet Med Assoc 205:1593–1598PubMed Dubey JP (1994) Toxoplasmosis. J Am Vet Med Assoc 205:1593–1598PubMed
15.
Zurück zum Zitat Lélu M, Villena I, Dardé ML, Aubert D, Geers R, Dupuis E, Marnef F, Poulle ML, Gotteland C, Dumètre A, Gilot-Fromont E (2012) Quantitative estimation of the viability of Toxoplasma gondii oocysts in soil. Appl Environ Microbiol 78:5127–5132PubMedCentralPubMedCrossRef Lélu M, Villena I, Dardé ML, Aubert D, Geers R, Dupuis E, Marnef F, Poulle ML, Gotteland C, Dumètre A, Gilot-Fromont E (2012) Quantitative estimation of the viability of Toxoplasma gondii oocysts in soil. Appl Environ Microbiol 78:5127–5132PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Montoya JG, Remington JS (2008) Management of Toxoplasma gondii Infection during pregnancy. Clin Infect Dis 47:554–566PubMedCrossRef Montoya JG, Remington JS (2008) Management of Toxoplasma gondii Infection during pregnancy. Clin Infect Dis 47:554–566PubMedCrossRef
17.
Zurück zum Zitat Liesenfeld O, Press C, Montoya JG, Gill R, Isaac-Renton JL, Hedman K, Remington JS (1997) False-positive results in immunoglobulin M (IgM) Toxoplasma antibody tests and importance of confirmatory testing: the Platelia Toxo IgM Test. J Clin Microbiol 35:174–178PubMedCentralPubMed Liesenfeld O, Press C, Montoya JG, Gill R, Isaac-Renton JL, Hedman K, Remington JS (1997) False-positive results in immunoglobulin M (IgM) Toxoplasma antibody tests and importance of confirmatory testing: the Platelia Toxo IgM Test. J Clin Microbiol 35:174–178PubMedCentralPubMed
18.
Zurück zum Zitat Wilson MJ, Remington S, Clavet C, Varney G, Press C, Ware D (1997) Evaluation of six commercial kits for detection of human immunoglobulin M antibodies to Toxoplasma gondii. J Clin Microbiol 35:3112–3115PubMedCentralPubMed Wilson MJ, Remington S, Clavet C, Varney G, Press C, Ware D (1997) Evaluation of six commercial kits for detection of human immunoglobulin M antibodies to Toxoplasma gondii. J Clin Microbiol 35:3112–3115PubMedCentralPubMed
19.
Zurück zum Zitat Gras L, Gilbert RE, Wallon M, Peyron F, Cortina-Borja M (2004) Duration of the IgM response in women acquiring Toxoplasma gondii during pregnancy: implications for clinical practice and cross-sectional incidence studies. Epidemiol Infect 132:541–548PubMedCentralPubMedCrossRef Gras L, Gilbert RE, Wallon M, Peyron F, Cortina-Borja M (2004) Duration of the IgM response in women acquiring Toxoplasma gondii during pregnancy: implications for clinical practice and cross-sectional incidence studies. Epidemiol Infect 132:541–548PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Gilbert R, Petersen E (2013) Toxoplasmosis and pregnancy. UptoDate Online. Accessed 16 October 2013 Gilbert R, Petersen E (2013) Toxoplasmosis and pregnancy. UptoDate Online. Accessed 16 October 2013
21.
Zurück zum Zitat Paquet C, Yudin MH (2013) Toxoplasmosis in Pregnancy: prevention, screening, and treatment. J Obstet Gynaecol Can 35:78–79PubMed Paquet C, Yudin MH (2013) Toxoplasmosis in Pregnancy: prevention, screening, and treatment. J Obstet Gynaecol Can 35:78–79PubMed
24.
Zurück zum Zitat Rudin C, Boubaker K, Raeber PA, Vaudaux B, Bucher HC, Garweg JG, Hoesli I, Kind C, Hohlfeld P (2008) Toxoplasmosis during pregnancy and infancy, a new approach for Switzerland. Swiss Med Wkly 138(Suppl 168):1–8 Rudin C, Boubaker K, Raeber PA, Vaudaux B, Bucher HC, Garweg JG, Hoesli I, Kind C, Hohlfeld P (2008) Toxoplasmosis during pregnancy and infancy, a new approach for Switzerland. Swiss Med Wkly 138(Suppl 168):1–8
25.
Zurück zum Zitat Röser D, Nielsen HV, Petersen E, Saugmann-Jensen P, Nørgaard-Pedersen PB (2010) Congenital toxoplasmosis—a report on the Danish neonatal screening programme 1999–2007. J Inherit Metab Dis 33(Suppl 2):S241–S247PubMedCrossRef Röser D, Nielsen HV, Petersen E, Saugmann-Jensen P, Nørgaard-Pedersen PB (2010) Congenital toxoplasmosis—a report on the Danish neonatal screening programme 1999–2007. J Inherit Metab Dis 33(Suppl 2):S241–S247PubMedCrossRef
26.
Zurück zum Zitat Miron D, Raz R, Luder A (2002) Congenital toxoplasmosis in Israel: to screen or not to screen. Isr Med Assoc J 4:119–122PubMed Miron D, Raz R, Luder A (2002) Congenital toxoplasmosis in Israel: to screen or not to screen. Isr Med Assoc J 4:119–122PubMed
27.
Zurück zum Zitat Khoshnood B, De Vigan C, Goffinet F, Leroy V (2007) Prenatal screening and diagnosis of congenital toxoplasmosis: a review of safety issues and psychological consequences for women who undergo screening. Prenat Diagn 27:395–403PubMedCrossRef Khoshnood B, De Vigan C, Goffinet F, Leroy V (2007) Prenatal screening and diagnosis of congenital toxoplasmosis: a review of safety issues and psychological consequences for women who undergo screening. Prenat Diagn 27:395–403PubMedCrossRef
28.
Zurück zum Zitat Cornu C, Bissery A, Malbos C, Garwig R, Cocherel C, Ecochard R, Peyron F, Wallon M (2009) Factors affecting the adherence to an antenatal screening programme: an experience with toxoplasmosis screening in France. Euro Surveill 14:21–25PubMed Cornu C, Bissery A, Malbos C, Garwig R, Cocherel C, Ecochard R, Peyron F, Wallon M (2009) Factors affecting the adherence to an antenatal screening programme: an experience with toxoplasmosis screening in France. Euro Surveill 14:21–25PubMed
29.
Zurück zum Zitat Sagel U, Kremer A, Mikolajczyk RT (2011) Incidence of maternal Toxoplasma infection in pregnancy in Upper Austria, 2000-2007. BMC Infect Dis 11:348PubMedCentralPubMedCrossRef Sagel U, Kremer A, Mikolajczyk RT (2011) Incidence of maternal Toxoplasma infection in pregnancy in Upper Austria, 2000-2007. BMC Infect Dis 11:348PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Hedman K, Lappalainen M, Seppala I, Makela O (1989) Recent primary Toxoplasma infection indicated by a low avidity of specific IgG. J Infect Dis 159:736–740PubMedCrossRef Hedman K, Lappalainen M, Seppala I, Makela O (1989) Recent primary Toxoplasma infection indicated by a low avidity of specific IgG. J Infect Dis 159:736–740PubMedCrossRef
32.
Zurück zum Zitat Roberts A, Hedman K, Luyasu V, Zufferey J, Bessieres JH, Blatz RM, Candolfi E, Decoster A, Enders G, Gross U, Guy E, Hayde M, Ho-Yen D, Johnson J, Lecolier B, Naessens A, Pelloux H, Thulliez P, Petersen E (2001) Multicenter evaluation of strategies for serodiagnosis of primary infection with Toxoplasma gondii. Eur J Clin Microbiol Infect Dis 20:467–474PubMed Roberts A, Hedman K, Luyasu V, Zufferey J, Bessieres JH, Blatz RM, Candolfi E, Decoster A, Enders G, Gross U, Guy E, Hayde M, Ho-Yen D, Johnson J, Lecolier B, Naessens A, Pelloux H, Thulliez P, Petersen E (2001) Multicenter evaluation of strategies for serodiagnosis of primary infection with Toxoplasma gondii. Eur J Clin Microbiol Infect Dis 20:467–474PubMed
33.
Zurück zum Zitat Cortina-Borja M, Tan HK, Wallon M, Paul M, Prusa A, Buffolano W, Malm G, Salt A, Freeman K, Petersen E, Gilbert RE, European Multicentre Study on Congenital Toxoplasmosis (EMSCOT) (2010) Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational prospective cohort study. PLoS Med 7:e1000351PubMedCentralPubMedCrossRef Cortina-Borja M, Tan HK, Wallon M, Paul M, Prusa A, Buffolano W, Malm G, Salt A, Freeman K, Petersen E, Gilbert RE, European Multicentre Study on Congenital Toxoplasmosis (EMSCOT) (2010) Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational prospective cohort study. PLoS Med 7:e1000351PubMedCentralPubMedCrossRef
34.
Zurück zum Zitat Gratzl R, Sodeck G, Platzer P, Jäger W, Graf J, Pollak A, Thalhammer T (2002) Treatment of toxoplasmosis in pregnancy: concentrations of spiramycin and neospiramycin in maternal serum and amniotic fluid. Eur J Clin Microbiol Infect Dis 21:12–16PubMedCrossRef Gratzl R, Sodeck G, Platzer P, Jäger W, Graf J, Pollak A, Thalhammer T (2002) Treatment of toxoplasmosis in pregnancy: concentrations of spiramycin and neospiramycin in maternal serum and amniotic fluid. Eur J Clin Microbiol Infect Dis 21:12–16PubMedCrossRef
35.
Zurück zum Zitat Desmonts G, Couvreur J (1979) Congenital toxoplasmosis: a prospective study of the offspring of 542 women who acquired toxoplasmosis during pregnancy. In: Thalhammer O, Pollak A, Baumgarten K (eds) Perinatal medicine: proceedings of the 6th European Congress, Vienna. Georg Thieme Publishers, Stuttgart, pp 51–60 Desmonts G, Couvreur J (1979) Congenital toxoplasmosis: a prospective study of the offspring of 542 women who acquired toxoplasmosis during pregnancy. In: Thalhammer O, Pollak A, Baumgarten K (eds) Perinatal medicine: proceedings of the 6th European Congress, Vienna. Georg Thieme Publishers, Stuttgart, pp 51–60
36.
Zurück zum Zitat Forestier F (1991) Les foetopathies infectieuses: prevention, diagnostic prenatal, attitude pratique. Presse Med 20:1448–1454PubMed Forestier F (1991) Les foetopathies infectieuses: prevention, diagnostic prenatal, attitude pratique. Presse Med 20:1448–1454PubMed
37.
Zurück zum Zitat Couvreur J, Desmonts G, Thulliez P (1988) Prophylaxis of congenital toxoplasmosis: effects of spiramycin on placental infection. J Antimicrob Chemother 22:193–200PubMedCrossRef Couvreur J, Desmonts G, Thulliez P (1988) Prophylaxis of congenital toxoplasmosis: effects of spiramycin on placental infection. J Antimicrob Chemother 22:193–200PubMedCrossRef
38.
Zurück zum Zitat Thiébaut R, Leroy V, Alioum A, Binquet C, Poizat G, Salmi LR, Gras L, Salamon R, Gilbert R, Chêne G (2006) Biases in observational studies of the effect of prenatal treatment for congenital toxoplasmosis. Eur J Obstet Gynecol Reprod Biol 124:3PubMedCrossRef Thiébaut R, Leroy V, Alioum A, Binquet C, Poizat G, Salmi LR, Gras L, Salamon R, Gilbert R, Chêne G (2006) Biases in observational studies of the effect of prenatal treatment for congenital toxoplasmosis. Eur J Obstet Gynecol Reprod Biol 124:3PubMedCrossRef
39.
Zurück zum Zitat Foulon W, Villena I, Stray-Pedersen B, Decoster A, Lappalainen M, Pinon JM, Jenum PA, Hedman K, Naessens A (1999) Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children’s sequelae at age 1 year. Am J Obstet Gynecol 180:410PubMedCrossRef Foulon W, Villena I, Stray-Pedersen B, Decoster A, Lappalainen M, Pinon JM, Jenum PA, Hedman K, Naessens A (1999) Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children’s sequelae at age 1 year. Am J Obstet Gynecol 180:410PubMedCrossRef
40.
Zurück zum Zitat Gilbert RE, Gras L, Wallon M, Peyron F, Ades AE, Dunn DT (2001) Effect of prenatal treatment on mother to child transmission of Toxoplasma gondii: retrospective cohort study of 554 mother-child pairs in Lyon, France. Int J Epidemiol 30:1303PubMedCrossRef Gilbert RE, Gras L, Wallon M, Peyron F, Ades AE, Dunn DT (2001) Effect of prenatal treatment on mother to child transmission of Toxoplasma gondii: retrospective cohort study of 554 mother-child pairs in Lyon, France. Int J Epidemiol 30:1303PubMedCrossRef
41.
Zurück zum Zitat Jones JL, Kruszon-Moran D, Wilson M, McQuillan G, Navin T, McAuley JB (2001) Toxoplasma gondii Infection in the United States: seroprevalence and Risk Factors. Am J Epidemiology 54:357–365CrossRef Jones JL, Kruszon-Moran D, Wilson M, McQuillan G, Navin T, McAuley JB (2001) Toxoplasma gondii Infection in the United States: seroprevalence and Risk Factors. Am J Epidemiology 54:357–365CrossRef
Metadaten
Titel
Survey of obstetrician-gynecologists in the United States about toxoplasmosis: 2012 update
verfasst von
Stephanie M. Davis
Britta L. Anderson
Jay Schulkin
Katherine Jones
Jodi Vanden Eng
Jeffrey L. Jones
Publikationsdatum
01.03.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 3/2015
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-014-3450-y

Weitere Artikel der Ausgabe 3/2015

Archives of Gynecology and Obstetrics 3/2015 Zur Ausgabe

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.